# US 2023/0265159 A1 · Method of compact peptide vaccines using residue optimization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265159 A1
- Document ID: US20230265159A1
- Status: Published application
- Kind: A1
- Application number: 18/192,274
- Filed: 2023-03-29
- Published: 2023-08-24
- Earliest claimed: 2020-12-07
- Assignees: Think Therapeutics, Inc.
- Applicants: Think Therapeutics, Inc.
- Inventors: David Kenneth GIFFORD; Brandon CARTER
- Web page: https://patentgrep.com/patent/US20230265159A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- G01N 33/56977: {HLA or MHC typing}
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 5/20: Probabilistic models
- G16B 15/20: Protein or domain folding
- G16B 20/30: Detection of binding sites or motifs
- G16B 20/40: Population genetics; Linkage disequilibrium
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 35/10: Design of libraries
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

A system for selecting an immunogenic peptide composition comprising a processor and a memory storing processor-executable instructions that, when executed by the processor, cause the processor to create a first peptide set by selecting a plurality of base peptides, wherein at least one peptide of the plurality of base peptides is associated with a disease, create a second peptide set by adding to the first peptide set a modified peptide, wherein the modified peptide comprises a substitution of at least one residue of a base peptide selected from the plurality of base peptides, and create a third peptide set by selecting a subset of the second peptide set, wherein the selected subset of the second peptide set has a predicted vaccine performance, wherein the predicted vaccine performance has a population coverage above a predetermined threshold, and wherein the subset comprises at least one peptide of the second peptide set.

## Claims

### Claim 1

A method of forming an immunogenic peptide composition, the method comprising:
using a processor to perform the steps of:
creating a first peptide set by selecting one or more peptide sequences, wherein each peptide sequence of the one or more peptide sequences is derived from a first target, and wherein the first target is a protein sequence associated with a tumor neoantigen, a pathogen proteome, or a self-protein;
creating a second peptide set by selecting two or more peptide sequences, wherein each peptide sequence of the two or more peptide sequences is derived from the first target, and wherein the second peptide set is larger than the first peptide set by one peptide sequence;
computing, with respect to the first peptide set, a first predicted vaccine performance value;
computing, with respect to the second peptide set, a second predicted vaccine performance value;
computing a first marginal predicted vaccine performance value by obtaining a difference between the first predicted vaccine performance value and the second predicted vaccine performance value;
computing a first weighted marginal predicted vaccine performance value based on the first marginal predicted vaccine performance value and a weight associated with the first target;
creating a third peptide set by selecting one or more peptide sequences, wherein each peptide sequence of the one or more peptide sequences is derived from a second target, and wherein the second target is a protein sequence associated with a tumor neoantigen, a pathogen proteome, or a self-protein;
creating a fourth peptide set by selecting two or more peptide sequences, wherein each peptide sequence of the two or more peptide sequences is derived from the second target, and wherein the fourth peptide set is larger than the third peptide set by one peptide sequence;
computing, with respect to the third peptide set, a third predicted vaccine performance value;
computing, with respect to the fourth peptide set, a fourth predicted vaccine performance value;
computing a second marginal predicted vaccine performance value by obtaining a difference between the third predicted vaccine performance value and the fourth predicted vaccine performance value;
computing a second weighted marginal predicted vaccine performance value based on the second marginal predicted vaccine performance value and a weight associated with the second target;
creating a fifth peptide set comprising:
the first peptide set or the second peptide set; and
the third peptide set or the fourth peptide set,
wherein creating the fifth peptide set is based on the first weighted predicted marginal vaccine performance value and the second weighted predicted marginal performance value;
performing an experimental assay to obtain a peptide-HLA immunogenicity metric for one or more peptide sequences of the fifth peptide set; and
forming an immunogenic peptide composition comprising the one or more peptide sequences of the fifth peptide set for which the experimental assay was performed.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first peptide set comprises two or more peptide sequences and the second peptide set comprises three or more peptide sequences.

### Claim 3 (depends on 2)

The method of claim 2, wherein the third peptide set comprises two or more peptide sequences and the fourth peptide set comprises three or more peptide sequences.

### Claim 4 (depends on 1)

The method of claim 1, wherein computing the first marginal predicted vaccine performance value and the second marginal predicted vaccine performance value comprises computing a population coverage.

### Claim 5 (depends on 4)

The method of claim 4, wherein the population coverage is computed based on a frequency of an HLA allele in a human population.

### Claim 6 (depends on 5)

The method of claim 5, wherein the population coverage is computed based on a frequency of at least three HLA alleles in the human population.

### Claim 7 (depends on 1)

The method of claim 1, wherein computing the first marginal predicted vaccine performance value and the second marginal predicted vaccine performance value comprises computing an expected number of peptide-HLA hits.

### Claim 8 (depends on 1)

The method of claim 1, wherein the weight associated with the first target is a probability of a presentation of the first target in a subject diagnosed with a disease.

### Claim 9 (depends on 1)

The method of claim 1, wherein the weight associated with the second target is a probability of a presentation of the second target in a subject diagnosed with a disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the first target is the protein sequence associated with the tumor neoantigen, wherein the tumor neoantigen is expressed in a subject diagnosed with cancer, and wherein the cancer is selected from the group consisting of pancreatic cancer, colon cancer, rectal cancer, kidney cancer, bronchus cancer, lung cancer, uterine cancer, cervical cancer, bladder cancer, liver cancer, and stomach cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the second target is the protein sequence associated with the tumor neoantigen, wherein the tumor neoantigen is expressed in a subject diagnosed with cancer, and wherein the cancer is selected from the group consisting of pancreatic cancer, colon cancer, rectal cancer, kidney cancer, bronchus cancer, lung cancer, uterine cancer, cervical cancer, bladder cancer, liver cancer, and stomach cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein computing the first marginal predicted vaccine performance value and the second marginal predicted vaccine performance value is based on an HLA type of a subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein computing the first marginal predicted vaccine performance value and the second marginal predicted vaccine performance value comprises computing an expected number peptide-HLA hits in the subject.

### Claim 14 (depends on 12)

The method of claim 12, wherein computing the first marginal predicted vaccine performance value and second marginal predicted vaccine performance value comprises computing an expected fraction of HLA alleles in a subject that has a minimum number of peptide-HLA hits, wherein the minimum number of peptide-HLA hits is based on a threshold.

### Claim 15 (depends on 1)

The method of claim 1, wherein each peptide sequence of the first peptide set, the second peptide set, the third peptide set, and the fourth peptide set is configured to bind to an HLA class I molecule or an HLA class II molecule expressed in a subject in vivo.
